Literature DB >> 16277551

The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.

Andrew Lloyd1, Emma McIntosh, Martin Price.   

Abstract

INTRODUCTION: Antiepileptic drugs (AEDs) have been shown to reduce the severity and frequency of seizures for most patients. However, many patients experience adverse effects in order to maintain seizure control. STUDY
DESIGN: A stated preference discrete choice experiment (DCE) was used to explore the preferences of people with epilepsy regarding the adverse effects and seizure control of AEDs.
METHODS: The main adverse effects of AEDs were identified through a literature search and expert consultation. In addition, a national epilepsy patient advocacy group helped to identify important attributes and commented on the attributes we had already identified. The DCE included five attributes related to adverse effects (alopecia, nausea, skin rash, concentration effects and weight change) plus seizure control and cost (to estimate willingness to pay [WTP]). A cost attribute was included in the DCE in order to estimate people's WTP for changes in attribute levels. Five hundred members of a national patient advocacy group with a diagnosis of epilepsy were presented with pairs of hypothetical drug profiles with varied levels of adverse effects, seizure control and cost; they were then asked to indicate which drug they preferred. Questions were also included to collect sociodemographic data (including income) and information regarding experience of adverse effects and medication. The survey was administered via the post and the Internet. Data were analysed using a random effects probit model.
RESULTS: A total of 148 surveys were returned. All attributes were significant and had the expected polarity, i.e. participants showed a preference for less severe adverse effects, greater seizure control and less cost. To achieve 100% seizure control and no adverse effects, participants were willing to pay 709 pounds sterlings (1105 US dollars) per month, 95% CI 451 pounds sterlings, 1278 pounds sterlings (1 pound sterling = 1.56 US dollars, 2002 exchange rate). Participants' WTP was significantly influenced by different adverse effects; for example, people with epilepsy were willing to pay only 174 pounds sterlings (271 US dollars) per month for a drug that provided seizure freedom but also caused hair loss. Segmented models showed that seizure frequency has a significant negative impact on respondents' income levels. Also, women were willing to pay twice as much as men to avoid weight gain. Participants were also willing to trade changes in seizure control for improvements in adverse effects.
CONCLUSION: Participants placed a high value on gaining total seizure control with no adverse effects. This study underlines the importance that people with epilepsy place on reducing adverse effects. The study also revealed how preferences for AEDs vary in different subgroups. Management of epilepsy is usually aimed at minimising seizures within a tolerable level of adverse effects. The present study suggests that people with epilepsy have strong preferences for reducing adverse effects as well as improving seizure control. These data may be considered useful when making medical management decisions in epilepsy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16277551     DOI: 10.2165/00019053-200523110-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  27 in total

Review 1.  Patient choice modules for summaries of clinical effectiveness: a proposal.

Authors:  M Holmes-Rovner; H Llewellyn-Thomas; V Entwistle; A Coulter; A O'Connor; D R Rovner
Journal:  BMJ       Date:  2001-03-17

2.  Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilisation.

Authors:  M Ryan
Journal:  Soc Sci Med       Date:  1999-02       Impact factor: 4.634

3.  Sharing decisions with patients: is the information good enough?

Authors:  A Coulter; V Entwistle; D Gilbert
Journal:  BMJ       Date:  1999-01-30

4.  Willingness to pay: a feasible method for assessing treatment benefits in epilepsy?

Authors:  K Stavem
Journal:  Seizure       Date:  1999-02       Impact factor: 3.184

Review 5.  Major system toxicities and side effects of anticonvulsants.

Authors:  A C Swann
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

6.  Establishing patient preferences for blood transfusion support: an application of conjoint analysis.

Authors:  M van der Pol; J Cairns
Journal:  J Health Serv Res Policy       Date:  1998-04

7.  Eliciting public preferences for healthcare: a systematic review of techniques.

Authors:  M Ryan; D A Scott; C Reeves; A Bate; E R van Teijlingen; E M Russell; M Napper; C M Robb
Journal:  Health Technol Assess       Date:  2001       Impact factor: 4.014

Review 8.  Quality of life in patients with epilepsy and impact of treatments.

Authors:  Patrizia Berto
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 9.  Life-threatening adverse events of antiepileptic drugs.

Authors:  S Arroyo; A de la Morena
Journal:  Epilepsy Res       Date:  2001-11       Impact factor: 3.045

10.  Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group.

Authors:  F Matsuo; D Bergen; E Faught; J A Messenheimer; A T Dren; G D Rudd; C G Lineberry
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

View more
  14 in total

1.  Andrew lloyd: a driving force in patient-centered outcomes research.

Authors:  John F P Bridges; Christopher I Carswell
Journal:  Patient       Date:  2008-12-01       Impact factor: 3.883

Review 2.  A descriptive review on methods to prioritize outcomes in a health care context.

Authors:  Inger M Janssen; Ansgar Gerhardus; Milly A Schröer-Günther; Fülöp Scheibler
Journal:  Health Expect       Date:  2014-08-25       Impact factor: 3.377

3.  How does patients' quality of life guide their preferences regarding aspects of asthma therapy?: a patient-preference study using discrete-choice experiment methodology.

Authors:  Andrew Lloyd; Emma McIntosh; Angela E Williams; Ad Kaptein; Klaus F Rabe
Journal:  Patient       Date:  2008-12-01       Impact factor: 3.883

Review 4.  Risk as an attribute in discrete choice experiments: a systematic review of the literature.

Authors:  Mark Harrison; Dan Rigby; Caroline Vass; Terry Flynn; Jordan Louviere; Katherine Payne
Journal:  Patient       Date:  2014       Impact factor: 3.883

5.  Retrospective analysis of the effectiveness of first-line antiepileptic drugs for generalized onset and unclassified epileptic seizures in Chinese children.

Authors:  Ying-Xue Ding; Li-Ping Zou; Ming-Sheng Ma; Ying Wang; Lu-Liang Meng; Fang Fang; Chang-Hong Ding
Journal:  Childs Nerv Syst       Date:  2010-08-06       Impact factor: 1.475

6.  Patient preferences for osteoporosis in Spain: a discrete choice experiment.

Authors:  J Darbà; G Restovic; L Kaskens; M A Balbona; A Carbonell; P Cavero; M Jordana; C Prieto; A Molina; I Padró
Journal:  Osteoporos Int       Date:  2010-09-14       Impact factor: 4.507

Review 7.  Epilepsy and brain tumors.

Authors:  Dario J Englot; Edward F Chang; Charles J Vecht
Journal:  Handb Clin Neurol       Date:  2016

8.  Patients' preferences for osteoporosis drug treatment: a discrete choice experiment.

Authors:  E W de Bekker-Grob; M L Essink-Bot; W J Meerding; H A P Pols; B W Koes; E W Steyerberg
Journal:  Osteoporos Int       Date:  2008-01-08       Impact factor: 4.507

9.  Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.

Authors:  Graham Powell; Emily A F Holmes; Catrin O Plumpton; Adele Ring; Gus A Baker; Ann Jacoby; Munir Pirmohamed; Anthony G Marson; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2015-08-22       Impact factor: 4.335

10.  Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments.

Authors:  Lina Eliasson; Anthony P Bewley; Farhan Mughal; Karissa M Johnston; Andreas Kuznik; Chloe Patel; Andrew J Lloyd
Journal:  Patient Prefer Adherence       Date:  2017-02-28       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.